• Northlands Road, Magee Campus

    BT48 7JL Londonderry

    United Kingdom

Calculated based on number of publications stored in Pure and citations from Scopus

Research activity per year

Personal profile


After his Biochemistry degree, Dr David Gibson worked at Randox Laboratories Ltd, where he was responsible for designing and commercialising novel biochip array diagnostic tests.

He was awarded a PhD in 2001 from the Centre for Cancer Research and Cell Biology, Queen’s University Belfast (QUB), for research which exposed the role of cysteine proteinases in brain tumour invasion.

During a Wellcome Trust Fellowship Dr Gibson investigated the role of inflammation in a hypoxia driven model of diabetic retinopathy at the Centre of Vision and Vascular Science, QUB.

Since 2003 Dr Gibson focused his research efforts on the discovery and validation of protein biomarkers which could improve the management of arthritis patients.

During his time at the Rooney laboratory in the Centre of Infection and Immunity, QUB he spearheaded the use of proteomic and bioinformatics strategies to discover clinically useful biomarker candidates. He also identified post translational modifications in the Vitamin D binding protein that may act as a modulator of inflammation in juvenile arthritis patients.

In 2009, Dr Gibson was awarded a prestigious travel fellowship from Arthritis Research UK to conduct mass spectrometry based research at the Duncan laboratory at the University of Colorado, Denver over two years.



Research Interests


In 2013 Dr Gibson took up his post as Lecturer in Personalised Medicine and his research is focused on adult rheumatoid arthritis (RA). He is particularly interested in the development of new prognostic and predictive tools to improve the clinical management of arthritis patients.

He employs novel proteomic based methods to robustly identify and quantify disease associated proteins in blood. He is also interested in the application of protein array technologies for autoantibody screening and flow cytometry in measuring B- and T-cell activation.

He has established research programmes in three key areas:
1. Biomarkers of response to disease modifying anti-rheumatic drugs.
2. Pharmacogenomic test development and implementation into healthcare to improve treatment efficacy and safety.
3. Alternate blood sampling methods to support home based monitoring of arthritis (BloodTrackR).

Ultimately, Dr Gibsons group will develop novel monitoring tools to help clinicians target those patients who do not respond well to current therapeutics or develop drug resistance over time. This could allow earlier more effective treatments in RA patients, thus preventing joint damage and reducing disability.


Teaching Interests


1. Biochemistry and Cell Biology
2. Inflammatory and Immunological Disease
3. DNA Sequencing and Omics technologies
4. Disease and Treatment 2

Administrative Roles

Research Group Lead, Personalised Medicine Centre


Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being
  • SDG 4 - Quality Education
  • SDG 9 - Industry, Innovation, and Infrastructure


  • RZ Other systems of medicine
  • QH301 Biology


Dive into the research topics where David Gibson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or